Evaluating immunotherapy for liver cancer in Chinese patients
A Real-world Study of Immunotherapy-based Combination Therapies in Chinese Patients With Hepatocellular Carcinoma
This study is testing how well immunotherapy treatments work for Chinese patients with liver cancer to see if they are safe and effective in real-life situations.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 11000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Nanjing, Jiangsu) |
| Trial ID | NCT06241326 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on Chinese patients diagnosed with hepatocellular carcinoma (HCC) to assess the safety and efficacy of immunotherapy-based combination therapies in real-world clinical settings. The study aims to gather and analyze data regarding the clinical characteristics, treatment modalities, and outcomes of HCC patients receiving these treatments. By understanding the effectiveness of these regimens, the research seeks to inform future treatment patterns for liver cancer in this population.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with hepatocellular carcinoma who may benefit from immunotherapy-based combination treatments.
Not a fit: Patients who are pregnant, lactating, or have other conditions deemed unsuitable by investigators may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective immunotherapy treatments for liver cancer, potentially improving patient outcomes.
How similar studies have performed: Other studies have shown promise in using immunotherapy for liver cancer, indicating that this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Aged after 18 years (18 is included). 2. Hepatocellular carcinoma diagnosed by pathology or imaging. 3. Patients assessed by researchers as potentially benefiting from receiving immunotherapy-based combination regimens. 4. For participants who have previously received treatment according to this protocol, a comprehensive pre-treatment assessment is required, including demographic information, tumor history, medical history, and baseline imaging examinations. 5. Patients voluntarily enroll in this study. Exclusion Criteria: 1. Pregnant or lactating women. 2. Other conditions regimented at investigators' discretion.
Where this trial is running
Nanjing, Jiangsu
- Jiangsu Province Hospital — Nanjing, Jiangsu, China (Recruiting)
Study contacts
- Study coordinator: Xuehao Wang, professor
- Email: mxrlwx19911990@163.com
- Phone: 86-025-68303211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.